Bruck Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 13-11-2024
- Paid Up Capital ₹ 2.68 Cr
as on 13-11-2024
- Company Age 40 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 24.65 Cr
as on 13-11-2024
- Satisfied Charges ₹ 7.10 Cr
as on 13-11-2024
- Revenue 3.12%
(FY 2024)
- Profit -8.49%
(FY 2024)
- Ebitda 5.35%
(FY 2024)
- Net Worth 11.52%
(FY 2024)
- Total Assets -0.74%
(FY 2024)
About Bruck Pharma
The Corporate was formerly known as Brucke Pharma Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.68 Cr.
The company currently has active open charges totaling ₹24.65 Cr. The company has closed loans amounting to ₹7.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shirish Kejriwal and Anshu Kejriwal serve as directors at the Company.
- CIN/LLPIN
U24239MH1984PTC416799
- Company No.
037865
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Aug 1984
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Bruck Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shirish Kejriwal  | Director | 25-May-2009 | Current |
| Anshu Kejriwal | Director | 02-Jul-2010 | Current |
Financial Performance of Bruck Pharma.
Bruck Pharma Private Limited, for the financial year ended 2024, experienced modest growth in revenue, with a 3.12% increase. The company also saw a slight decrease in profitability, with a 8.49% decrease in profit. The company's net worth Soared by an impressive increase of 11.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bruck Pharma?
In 2023, Bruck Pharma had a promoter holding of 92.91% and a public holding of 7.08%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Brucke Biocare Private LimitedActive 12 years 8 monthsShirish Kejriwal and Anshu Kejriwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Aug 2024 | ₹1.50 Cr | Open |
Others Creation Date: 24 Feb 2023 | ₹4.89 Cr | Open |
Others Creation Date: 24 Feb 2023 | ₹3.09 Cr | Open |
How Many Employees Work at Bruck Pharma?
Bruck Pharma has a workforce of 121 employees as of Nov 13, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bruck Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bruck Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
